Sign up
Pharma Capital

ValiRx given US patent boost for its lead therapeutic compound

VAL201 is currently in a Phase I/II study that is assessing safety and tolerability and its effect in the treatment of prostate cancer and other solid tumours
Prostate Cancer UK
So far, VAL201 has met and exceeds the predicted safety and tolerability criteria set for the trial

ValiRx PLC (LON:VAL) saw its shares tick higher on news it has received positive news regarding the US patent application for its lead therapeutic compound, VAL201.

The United States of America patent and trademark office has given notice of allowance for the US Patent Application No.14/575065, otherwise known by the snappy title “Anti-Androgen Peptides and Uses Thereof in Cancer Therapy".

READ: ValiRx given the green light to accelerate progress of prostate cancer drug after encouraging early results

VAL201 is currently in a Phase I/II study that is assessing safety and tolerability and its effect in the treatment of prostate cancer and other solid tumours.

The patent application covers the molecule and use of compounds in pharmaceutically acceptable products. The patent coverage also includes a wide variety of derivatives, modifications and analogues of the compounds and their mode of action; furthermore, the protection sought includes therapeutic formulations with associated delivery systems.

ValiRx said allowance of this US patent will represent one of the cornerstones of its commercial strategy, as ValiRx has already secured patent protection in several other territories, including Europe.

"It is timely and very exciting to receive this notification of allowance for the VAL201 patent,” said Satu Vainikka, the chief executive officer of ValiRx, who noted that the approval comes only weeks after the company received approval from the UK Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee for the company to expand its VAL201.

READ: ValiRx awarded fifth US patent for VAL401 cancer drug

“This US allowance means we can proceed to strengthen the VAL201 patent portfolio and, once granted, will provide ValiRx with patent protection in all its largest commercial markets globally. ValiRx looks forward optimistically to its future prospects," he added.

In afternoon trading, ValiRX shares were 0.5%, or 0.02p higher at 4.88p, having eased back from a session peak of 6.10p.

 -- Adds share price --

Why Invest In ValiRx Plc? Read More Here

Register here to be notified of future VAL Company articles
View full VAL profile View Profile
View All

Related Articles

US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.